1 PRODUCT MONOGRAPH - DVT ORGARAN Danaparoid Sodium ...

4. Boneu D, Buchanan MR, Cade JF, et al. Effects of heparin, its low molecular weight
fractions and other glycosaminoglycans on thrombus growth in vivo. Thromb Res 1985;
40: 81-9.
5. Bradbrook, I.D., Magnani, H.N., Moelker, H.C.T., Morrison, P.J., Robinson, J., Rogers,
H.J., Spector, R.G., Dinther,T. van and Wijnand, H.P. Org 10172: A low molecular
weight heparinoid anticoagulant with a long half-life in man. Br J Clin Pharmacol 1987;
23:667-675.
6. Chong, B.H., Ismail, F., Cade, J., Gallus, A.S., Gordon, S. and Chesterman, C.N.
Heparin-Induced Thrombocytopenia: Studies with a New Low Molecular Weight
Heparinoid, Org 10172. Blood 1989; 73:1592-1596.
7. Danhof, M., de Boer, A., Magnani, H.N., Stiekema, J.C.J. Pharmacokinetic
considerations on ORGARAN (Org 10172) therapy. Haemostasis 1992; 22:73-84.
8. Doty JR, Alving BM, McDonnell BM, Ondra SL. Heparin-induced thrombocytopenia in
the neurosurgical patient. Neurosurg 1986;19:69-72.
9. Frei, U., Wilks, M.F., Boehmer, S., Crisp-Lindgren, N., Schwarzrock, R., Stiekema, J.C.J.
and Koch, K.M. Gastrointestinal Blood Loss in Haemodialysis Patients During Use of a
Low-molecular-weight Heparinoid Anticoagulant. Nephrol Dial Transplant 1988;
3:434-439.
10. Gerhart, T.N., Yett, H.S., Robertson, L.K., Lee, M.A., Smith, M., Salzman, E.W. Low-
Molecular-Weight Heparinoid compared with Warfarin for prophylaxis of Deep-vein
thrombosis in patients who are operated on for fracture of the hip. J Bone Joint Surg
1991; 73:494-502.
11. Gibson J, Uhr E, Motum P, Rickard KA, Kronenberg H. Platelet aggregometry for the
28